People With Osteoporosis Can Walk-BEST to Reduce Fall and Fracture Risk (Walk-BEST)
29 mai 2026 mis à jour par: Suzanne Morin, McGill University Health Centre/Research Institute of the McGill University Health Centre
The aim of the Walk BEST study is to provide evidence that it is feasible to implement the technology assisted gait- focused walking program Walk-BEST™ in older adults with osteoporosis, and that this program is acceptable to this population.
Aperçu de l'étude
Statut
Recrutement
Les conditions
Intervention / Traitement
Description détaillée
The Walk-BEST™ technology assisted gait optimization program has demonstrated effectiveness in improving gait pattern and walking capacity without adverse events in people living with Parkinson's and Multiple Sclerosis. What is not known and the topic of this pilot and feasibility study is whether older people with osteoporosis will engage successfully with this program, since they do not have a diagnosis of a disabling condition affecting gait and may be unaware that their cautious method of walking exposes them to higher risk of falls and fractures rather than protecting them.
A randomized pilot and feasibility study (PAFS) will be conducted with groups randomized in a 1:1 ratio. Participants will be randomly assigned to either 1) immediate receipt of the Walk-BEST™ program; or 2) wait-list control and delayed receipt of Walk-BEST™ program 3 months post-randomization.
Participants will receive a copy of a proprietary workbook with instructions on simple exercises targeting strength, flexibility, and balance to facilitate a better walking pattern, as well as both 3-5 remote sessions with an exercise professional to practice walking well and to learn how to use the Heel2ToeTM sensor, and two technology phone calls with a research team member, over the first 4 weeks of the intervention. This personal gait training period will be followed by independent home practice over 2 months, during which participants will be instructed to practice walking with the sensor for a minimum period of 6 min, twice a day and to complete three exercises from their workbook at least twice a week.
There will be three on-site study visits at 3-month intervals: one for initial assessment, and two for reassessment.
Type d'étude
Interventionnel
Inscription (Estimé)
28
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Velizara Garkova, MSc
- Numéro de téléphone: 47071 514-934-1934
- E-mail: velizara.garkova@rimuhc.ca
Lieux d'étude
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3S5
- Recrutement
- Research Institute of the McGill University Health Centre
-
Contact:
- Numéro de téléphone: 5149341934
-
Chercheur principal:
- Suzanne Morin, MD
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- men and women 70 years and older
- able to walk independently with or without a walking aid
- experienced a prior fracture after the age of 40, OR two falls in the past 12 months, OR who have a bone mineral density test (done as part of routine clinical evaluation) with a T-score < -2.5, OR on a Health Canada-approved anti-osteoporosis medication (oral or intravenous bisphosphonate, denosumab, teriparatide, or romozosumab) to reduce fracture risk or on a bisphosphonate drug holiday (planned treatment interruption)
Exclusion Criteria:
- fracture sustained in the past 12 months
- unable to walk unsupervised because of active medical or neurocognitive reasons
- unable to provide informed consent, or cannot communicate in English or French
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Walk-BEST Immediate
Assigned to receive the Heel2Toe sensor and Walk BEST intervention right away.
|
Heel2Toe is a new generation of wearables that provides real-time auditory feedback when the person takes a good step, one in which the step is initiated with a strong heel strike.
Co-designed, evidence-based technology-assisted, therapeutic walking program developed by physiotherapy researchers, clinicians, and frail and non-frail seniors.
It consists of training elements (derived through international consensus and endorsed by 600 older Canadians) for optimal gait pattern with the use of a biofeedback device, the Heel2Toe™ sensor, which is introduced to reinforce the gait optimizing training and encourage home practice.
Autres noms:
|
|
Comparateur actif: Walk-BEST Delayed
Assigned to receive the Heel2Toe sensor and Walk BEST intervention after a delay of 3 months.
|
Heel2Toe is a new generation of wearables that provides real-time auditory feedback when the person takes a good step, one in which the step is initiated with a strong heel strike.
Co-designed, evidence-based technology-assisted, therapeutic walking program developed by physiotherapy researchers, clinicians, and frail and non-frail seniors.
It consists of training elements (derived through international consensus and endorsed by 600 older Canadians) for optimal gait pattern with the use of a biofeedback device, the Heel2Toe™ sensor, which is introduced to reinforce the gait optimizing training and encourage home practice.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Study recruitment rates (feasibility objective)
Délai: 3 months
|
The study will be considered feasible if the investigator can recruit 28 participants
|
3 months
|
|
Study retention rates (feasibility objective)
Délai: 9 months
|
The study will be considered feasible if ≥ 75 % of the sample completes the final assessment
|
9 months
|
|
Adherence to intervention (feasibility objective)
Délai: 9 months
|
The intervention will be considered feasible if participants complete ≥ 65% of the prescribed number of walking sessions at the 6-month follow-up.
|
9 months
|
|
Perceived acceptability and usability of the Heel2Toe sensor (feasibility objective)
Délai: 9 months
|
The acceptability outcomes will be based on an exit debriefing questionnaire.
Usability of the Heel2Toe sensor will be quantified with items from the Digital Health Devices Usability Indicators.
|
9 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Functional walking capacity
Délai: Change from Baseline to 3 months, 6 months
|
Six Minute Walk Test (6MWT)
|
Change from Baseline to 3 months, 6 months
|
|
Grip strength
Délai: Change from Baseline to 3 months, 6 months
|
Hand Dynamometer
|
Change from Baseline to 3 months, 6 months
|
|
Balance
Délai: Change from Baseline to 3 months, 6 months
|
Mini-Best Test (0-28; higher is better)
|
Change from Baseline to 3 months, 6 months
|
|
Functional leg muscle strength
Délai: Change from Baseline to 3 months, 6 months
|
30-second Chair stand test
|
Change from Baseline to 3 months, 6 months
|
|
Fear of falling
Délai: Change from Baseline to 3 months, 6 months
|
6-Item Revised Fear of Falling Questionnaire (6-24, lower is better)
|
Change from Baseline to 3 months, 6 months
|
|
Physical activity
Délai: Change from Baseline to 3 months, 6 months
|
Physical Activity Scale for the elderly (0-400+; higher is better)
|
Change from Baseline to 3 months, 6 months
|
|
Lower limb function
Délai: Change from Baseline to 3 months, 6 months
|
Lower Extremity Functional Scale (0-80; higher is better)
|
Change from Baseline to 3 months, 6 months
|
|
Quality of Life
Délai: Change from Baseline to 3 months, 6 months
|
Older Persons Active Living Related Quality of Life (8-32, higher is better)
|
Change from Baseline to 3 months, 6 months
|
|
Falls
Délai: Change from Baseline to 3 months, 6 months
|
Number of falls reported in the falls calendar
|
Change from Baseline to 3 months, 6 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Angular velocity of ankle during three phases of gait cycle, heel-strike, push-off, swing averaged over a walk of at least 50 steps
Délai: Change from Baseline to 3 months, 6 months
|
Degrees per second
|
Change from Baseline to 3 months, 6 months
|
|
Co-efficient of variation of angular velocity of ankle during three phases of gait cycle, heel-strike, push-off, swing averaged over a walk of at least 50 steps
Délai: Change from Baseline to 3 months, 6 months
|
Degrees per second
|
Change from Baseline to 3 months, 6 months
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Les enquêteurs
- Chercheur principal: Suzanne Morin, MD, RI-MUHC
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
7 mai 2026
Achèvement primaire (Estimé)
1 mai 2027
Achèvement de l'étude (Estimé)
1 mai 2027
Dates d'inscription aux études
Première soumission
25 mai 2026
Première soumission répondant aux critères de contrôle qualité
29 mai 2026
Première publication (Réel)
2 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
2 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
29 mai 2026
Dernière vérification
1 mai 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2026-12401
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .